{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:53Z","timestamp":1792985753941,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009148","name":"Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["DS-8201"],"award-info":[{"award-number":["DS-8201"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006413","name":"Ariad Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006676","name":"Lilly Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.esmoop.2022.100553","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T01:00:30Z","timestamp":1660179630000},"page":"100553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"H.S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-W.","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2022.100553_bib1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2022.100553_bib2","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5-6","key":"10.1016\/j.esmoop.2022.100553_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/prca.201300105","article-title":"Cathepsin B: multiple roles in cancer","volume":"8","author":"Aggarwal","year":"2014","journal-title":"Proteomics Clin Appl"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100553_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100553_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112136","article-title":"Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients","volume":"9","author":"Ruan","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100553_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100553_bib7","doi-asserted-by":"crossref","unstructured":"Modi S, Saura C, Yamashita T, et\u00a0al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Presented at San Antonio Breast Cancer Sympsoium. December 8-11, 2020; San Antonio, TX, virtual. Abstract PD3-06.","DOI":"10.1158\/1538-7445.SABCS20-PD3-06"},{"key":"10.1016\/j.esmoop.2022.100553_bib8","doi-asserted-by":"crossref","unstructured":"Saura Manich C, Modi S, Krop I, et\u00a0al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01). Presented at European Society for Medical Oncology Congress. September 16-21, 2021; Paris, France, virtual. Abstract 279P.","DOI":"10.1016\/j.annonc.2021.08.562"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100553_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100553_bib17","doi-asserted-by":"crossref","unstructured":"Curigliano G, Dunton K, Rosenlund M, et\u00a0al. Patient-reported outcomes from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Presented at ESMO Breast Cancer 2022. May 3-5, 2022; Berlin, Germany, virtual. Abstract 163O.","DOI":"10.1016\/j.annonc.2022.03.182"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100553_bib18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2022.100553_bib19","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100553_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100553_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100553_bib22","article-title":"A\u00a0phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma","volume":"38","author":"Fuchs","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2022.100553_bib23","article-title":"A\u00a0phase Ib\/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)","volume":"39","author":"Janjigian","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100553_bib25","doi-asserted-by":"crossref","unstructured":"Geyer CE, Jr, Untch M, Prat A, et\u00a0al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05). Presented at San Antonio Breast Cancer Sympsoium. December 8-11, 2020; San Antonio, TX, virtual. Abstract OT-03-01.","DOI":"10.1158\/1538-7445.SABCS20-OT-03-01"},{"key":"10.1016\/j.esmoop.2022.100553_bib26","doi-asserted-by":"crossref","unstructured":"Harbeck N, Boileau J-F, Modi S, et\u00a0al. A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). Presented at San Antonio Breast Cancer Sympsoium. December 7-10, 2020; San Antonio, TX, virtual. Abstract OT1-12-04.","DOI":"10.1158\/1538-7445.SABCS21-OT1-12-04"},{"issue":"17","key":"10.1016\/j.esmoop.2022.100553_bib27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2022.100553_bib29","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2022.100553_bib30","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100553_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100553_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","article-title":"Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review","volume":"26","author":"Jordan","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100553_bib36","first-page":"277","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2022.100553_bib37","author":"Aapro"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100553_bib38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers14041022","article-title":"Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an Italian expert panel","volume":"14","author":"Bianchini","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100553_bib39","first-page":"1533","article-title":"Anticipatory nausea and vomiting","volume":"19","author":"Roscoe","year":"2011","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100553_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000511049","article-title":"Management of chemotherapy-induced nausea and vomiting with trastuzumab deruxtecan: a case series","volume":"16","author":"Stankowicz","year":"2021","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100553_bib41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100553_bib42","first-page":"825","article-title":"Management of neutropenia in cancer patients","volume":"10","author":"Lustberg","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100553_bib43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"28","key":"10.1016\/j.esmoop.2022.100553_bib44","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2022.100553_bib45","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100553_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100553_bib47","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100553_bib48","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100553_bib49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.abd.2020.03.005","article-title":"Scalp cooling to prevent chemotherapy-induced alopecia","volume":"95","author":"Silva","year":"2020","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100553_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100553_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.esmoop.2022.100553_bib53","unstructured":"ClinicalTrials.gov. Scalp cooling in MBC. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04986579. Accessed February 2, 2022."},{"issue":"3","key":"10.1016\/j.esmoop.2022.100553_bib54","article-title":"Prevention and treatment of chemotherapy-induced alopecia","volume":"10","author":"Rossi","year":"2020","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100553_bib55","first-page":"93","article-title":"Oncology section EDGE Task Force on Cancer: measures of cancer-related fatigue\u2014a systematic review","volume":"36","author":"Fisher","year":"2018","journal-title":"Rehab Oncol"},{"key":"10.1016\/j.esmoop.2022.100553_bib56","series-title":"StatPearls","article-title":"Interstitial lung disease","author":"Antoine","year":"2021"},{"key":"10.1016\/j.esmoop.2022.100553_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2213-0802-2-4","article-title":"Diagnosis and management of interstitial lung disease","volume":"2","author":"Meyer","year":"2014","journal-title":"Transl Respir Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100553_bib58","doi-asserted-by":"crossref","first-page":"967","DOI":"10.7150\/ijms.32752","article-title":"Management of chronic respiratory failure in interstitial lung diseases: overview and clinical insights","volume":"16","author":"Faverio","year":"2019","journal-title":"Int J Med Sci"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100553_bib59","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100553_bib60","doi-asserted-by":"crossref","unstructured":"Powell CA, Modi S, Iwata H, et\u00a0al. Pooled analysis of drug-related interstitial lung disease in 8 single-arm trastuzumab deruxtecan studies. Presented at American Association for Cancer Research Annual Meeting. April 10-15 and May 17-21, 2021; Philadelphia, PA. Abstract CT167.","DOI":"10.1158\/1538-7445.AM2021-CT167"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100553_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100553_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100553_bib63","doi-asserted-by":"crossref","unstructured":"Powell CA, Modi S, Iwata H, et\u00a0al. Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Presented at European Society for Medical Oncology Breast Cancer. May 5-8, 2021; Virtual. Abstract 92O.","DOI":"10.1016\/j.annonc.2021.03.106"},{"key":"10.1016\/j.esmoop.2022.100553_bib64","unstructured":"ClinicalTrials.gov. A study of tucatinib plus trastuzumab deruxtecan in HER2+ breast cancer. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04539938. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib65","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2- positive metastatic breast cancer (DESTINY-Breast09). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04784715. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib66","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan alone or in combination with anastrozole for the treatment of early stage HER2 low, hormone receptor positive breast cancer. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04553770. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib67","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan with nivolumab in advanced breast and urothelial cancer. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03523572. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib68","unstructured":"ClinicalTrials.gov. DS8201a and pembrolizumab in participantswith locally advanced\/metastatic breast or non-small cell lung cancer. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04042701. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib69","unstructured":"ClinicalTrials.gov. Testing the combination of two anti-cancer drugs, DS-8201a and AZD6738, for the treatment of patients with advanced solid tumors expressing the HER2 protein or gene, the DASH trial. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04704661. Accessed February 2, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib70","unstructured":"ClinicalTrials.gov. A phase 1b\/2 study of T-DXd combinations in HER2-positive metastatic breast cancer (DB-07). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04538742. Accessed February 24, 2022."},{"key":"10.1016\/j.esmoop.2022.100553_bib71","doi-asserted-by":"crossref","unstructured":"Hamilton E, Shapiro CL, Petrylak D, et\u00a0al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Presented at San Antonio Breast Cancer Sympsoium. December 8-11, 2020; San Antonio, TX, virtual. Abstract PD3-07.","DOI":"10.1158\/1538-7445.SABCS20-PD3-07"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:48:49Z","timestamp":1778834929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2059702922001818"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100553"}}